Apaziquone for Nonmuscle Invasive Bladder Cancer: Where Are We Now?
Apaziquone for Nonmuscle Invasive Bladder Cancer: Where Are We Now?
Urol Clin North Am. 2020 Feb;47(1):73-82
Authors: Arends TJH, Alfred Witjes J
Abstract
Apaziquone is an interesting drug for intravesical use in patients with nonmuscle invasive bladder cancer; however, more research is needed to prove its actual benefit. Although the apaziquone trials demonstrate the potential of this new drug, the singular phase 3 trials did not reach their primary endpoint. To date, no new trials are recruiting, so the development of apaziquone seems to have stopped.
PMID: 31757302 [PubMed - in process]
Source: The Urologic Clinics of North America - Category: Urology & Nephrology Authors: Arends TJH, Alfred Witjes J Tags: Urol Clin North Am Source Type: research